• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

NME1+NME2 Polyklonaler Antikörper

NME1+NME2 Polyklonal Antikörper für WB, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, Indirect ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 33046-1-PBS

Synonyme

C-myc purine-binding transcription factor PUF, EC:2.7.13.3, EC:2.7.4.6, Histidine protein kinase NDKB, NDK A

Filter:
  • Western Blot (WB) analysis of various lysates using NME1+NME2 Polyclonal antibody (33046-1-AP)

    WB analysis using 33046-1-AP (same clone as 33046-1-PBS)

    Various lysates were subjected to SDS PAGE followed by western blot with 33046-1-AP (NME1-NME2 antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 33046-1-PBS in a different storage buffer formulation.

Geprüfte Anwendungen

Produktinformation

33046-1-PBS bindet in WB, Indirect ELISA NME1+NME2 und zeigt Reaktivität mit human

Getestete Reaktivität human
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen NME1+NME2 fusion protein Ag37892
Vollständiger Name NME1-NME2 readthrough transcript
Berechnetes Molekulargewicht17 kDa / 20 kDa
Beobachtetes Molekulargewicht17 kDa, 20 kDa
GenBank-ZugangsnummerBC107894
Gene symbol NME1-NME2
Gene ID (NCBI) 654364
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

NME1 and NME2 are associated with metastatic tumor suppression. NME1 and NME2 are multispecificity kinases phosphorylating serine, threonine, histidine, and aspartic acid residues of substrate proteins (PMID: 39032654). NME1 can catalyze the transfer of the terminal phosphate group of nucleoside triphosphates to nucleoside diphosphates to generate nucleoside triphosphates, which is crucial for DNA synthesis and repair. It also participates in cell signal transduction, proliferation, differentiation, and apoptosis. Reduced expression of NME1 is associated with increased tumor metastasis. For instance, in breast cancer, gastric cancer, and other malignancies, restoring NME1 expression can inhibit tumor invasion and metastasis. Similar to NME1, NME2 possesses nucleoside diphosphate kinase activity, participating in nucleotide metabolism and cell signaling regulation. It can form hexameric complexes with NME1 and also exists as homohexamers. Its functions overlap with those of NME1 to some extent but also exhibit unique roles in certain physiological processes. NME2 is involved in tumor metastasis regulation. However, its expression changes and specific mechanisms in different cancers may vary. In some tumors, NME2 expression is downregulated, while in others, it may be upregulated. For example, in hepatocellular carcinoma, reduced NME2 expression is associated with tumor progression and poor prognosis, whereas in ovarian cancer, elevated NME2 expression may promote tumor cell proliferation and metastasis.